semaglutide competitors FirstpostNews: Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent Do the New Obesity Drugs

However, it is essential to discuss this topic with your GP or a specialist rather than attempting to source or use unlicensed medicines independently

Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying

The pink label is easy to spot and prevents confusion with the green starter dose

It is not a medication

This means more people can stay on tirzepatide at effective doses compared to semaglutide, which is a meaningful advantage when the goal is long-term use